drugset / Trial / NCT00818870

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870

Phase 1 Completed 60 enrolled Vecta Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The study is designed to assess and compare the effect of Vecam 40/300, Vecam 20/300 and Omeprazole 20 mg (a standard FDA approved GERD treatment) on the control of gastric pH.

Timeline

Start
2008-12
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omeprazole Other / unclassified 20 mg Oral
Comparator Omeprazole Other / unclassified 40 mg Oral
Subject Vecam Unknown 300 mg Oral